Penumbra, Inc. (PEN) Stock
PEN Key Statistics
About Penumbra, Inc.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
CEO: Adam Elsesser. Company website
PEN — Frequently Asked Questions
What is the PEN stock price today?
Penumbra, Inc. (PEN) trades at $321.72, up 0.08% on the day, as of Nov 12, 2026 09:30 UTC.
What is Penumbra, Inc.'s market cap?
Penumbra, Inc. has a market capitalisation of $12.68B, calculated from the live PEN share price and shares outstanding.
What is the P/E ratio of PEN?
PEN trades at a trailing P/E of 81.04, from earnings per share of $3.97 over the last twelve months.
How much revenue does Penumbra, Inc. make?
Penumbra, Inc. generated revenue of $1.56B over the trailing twelve months, which puts the stock at 8.13 times sales.
What is the 52-week range for PEN?
PEN has traded between $259.14 and $362.41 over the past 52 weeks, and the last price is 11.2% below that high.
Is Penumbra, Inc. profitable?
Yes. Penumbra, Inc. keeps 10.06% of revenue as net income over the trailing twelve months.
What is the analyst price target for PEN?
Wall Street analysts rate PEN Hold, with an average price target of $320.00, 0.5% below the current price.
What sector is Penumbra, Inc. in?
Penumbra, Inc. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Who is the CEO of Penumbra, Inc.?
Adam Elsesser is the chief executive of Penumbra, Inc., which employs 4,700 people.
Where can I track PEN in real time?
QFI Terminal shows PEN with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See PEN live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PEN in Terminal See plans